""

LifeVantage Corporation, a leading provider of nutrigenomics and biohacking products, recently held its Q2 2026 earnings call. On the call, company executives discussed the financial performance for the quarter ended December 31, 2025. LifeVantage reported revenue of $63.8 million, a 12% increase from the same period last year. The company attributed this growth to increased sales in its US and international markets, as well as the expansion of its product offerings. LifeVantage's CEO, Steve Fife, highlighted the company's progress in its core business segments, including its flagship Protandim product line. The company also reported a net income of $4.3 million, or $0.23 per diluted share, for the quarter. As a key player in the health and wellness industry, LifeVantage's strong quarterly performance reflects the growing demand for nutrigenomics and biohacking solutions. With its continued focus on innovation and customer engagement, the company is well-positioned for long-term growth and success.